Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Deepak Bhatt, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Summary

• On February 1, 2025, Deepak Bhatt, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units.
• These units will be converted into shares of common stock upon settlement, which occurs when Bhatt ceases to be a director or at a previously specified future date.
• The price per unit was $58.95.
• Following the transaction, Bhatt beneficially owns 14,488.414 deferred share units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard Form 4 filing indicating a director's acquisition of deferred share units, which is part of their compensation.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's continued investment in the company.

Stakeholder Impact

• The acquisition of deferred share units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Deferred Share Units, Director, Form 4, BMY, Bristol-Myers Squibb, Beneficial Ownership